CNSide Diagnostics, a leader in precision diagnostics for central nervous system (CNS) cancers, is excited to announce the addition of Elaine Luckey as the company’s new Director of Quality.

Elaine brings extensive experience in quality management systems, regulatory compliance, and laboratory operations, making her a valuable addition to the CNSide team as it continues to advance the company’s mission of delivering highly sensitive, reliable, and CLIA-accredited diagnostics for patients with leptomeningeal metastases (LM) and other CNS cancers.

In this leadership role, Elaine will oversee quality assurance programs across CNSide’s clinical laboratory operations, ensuring the company continues to meet rigorous industry standards and federal regulations while maintaining its commitment to innovation and patient-centered care.

“Elaine’s expertise in quality systems and regulatory excellence will strengthen our ability to deliver trusted diagnostics at scale,” said Russell Bradley, President and General Manager. “Her leadership will help ensure that every test performed through our CNSide® platform meets the highest standards of accuracy and reliability.”

Supporting CNSide’s Mission to Transform CNS Cancer Care

At CNSide Diagnostics, we are dedicated to improving outcomes for patients with CNS cancers by providing physicians with highly sensitive cerebrospinal fluid (CSF) assays that support:

• Early and accurate detection of tumor cells in the central nervous system
• Real-time monitoring of disease progression and treatment response
• Data-driven therapeutic decisions to help physicians personalize care

The addition of talented leaders like Elaine reflects CNSide’s commitment to excellence in laboratory operations, compliance, and innovation — ensuring providers can rely on accurate and actionable diagnostic insights.

Learn More About Our Team & Mission

Meet the CNSide Team and Explore Our Mission: CNSide Mission & Values
About CNSide® Diagnostics: CNSide Official Website

#CNSide #Diagnostics #Biotech #HealthcareInnovation #Oncology #CancerDiagnostics #PrecisionMedicine #LifeSciences #Biotechnology #Healthcare #NewHire